Company: Johnson & Johnson (Janssen)
Tags: territory, management
My DM keeps telling us Tremfya's IL-23 mechanism gives us unique advantages that Skyrizi can't match. What he doesn't say is our formulary position is eroding quarter by quarter. I've watched Skyrizi go preferred on four plans in my territory in the last eight months. Tremfya is a good drug but AbbVie has an infrastructure for dermatology that Janssen just doesn't match right now. Speaker programs, KOL relationships, patient support — they're outspending us everywhere. I'm not saying Tremfya is done but I'm also not going to pretend we're competing on a level playing field. Morale on the team
6 upvotes · 0 comments